Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine piece tablets (TCMP) in China. The company offers advanced, fine, and regular TCMP products, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. As of March 31, 2022, it had an end-customer base of 68 pharmaceutical companies, 14 chain pharmacies, and 20 hospitals in 10 provinces and municipalities in China. The company was founded in 2005 and is headquartered in Taizhou, China.

China SXT Pharmaceuticals, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

TAIZHOU, CHINA, MARCH 17, 2025 (GLOBE NEWSWIRE) -- CHINA SXT PHARMACEUTICALS, INC. (NASDAQ: SXTC) (THE COMPANY), A SPECIALTY PHARMACEUTICAL COMPANY FOCUSING ON THE RESEARCH, DEVELOPMENT, MANUFACTURING, MARKETING, AND SALES OF TRADITIONAL CHINESE MEDICINE PIECES (TCMPS), INCLUDING ADVANCED TCMPS (DIRECTLY-ORAL TCMP AND AFTER-SOAKING-ORAL TCMP), FINE TCMPS, REGULAR TCMPS, AND TCM HOMOLOGOUS SUPPLEMENTS (TCMHS), TODAY ANNOUNCED THAT THE COMPANY RECEIVED A WRITTEN NOTIFICATION (THE COMPLIANCE NOTICE) FROM THE LISTING QUALIFICATIONS DEPARTMENT OF THE NASDAQ STOCK MARKET LLC (NASDAQ) DATED MARCH 13, 2025, INFORMING THE COMPANY THAT IT HAS REGAINED COMPLIANCE WITH THE NASDAQ LISTING RULE 5550(A)(2) (MINIMUM BID PRICE REQUIREMENT) AND THE MATTER IS CLOSED.

CHINA SXT PHARMACEUTICALS HAS REGAINED COMPLIANCE WITH NASDAQ'S MINIMUM BID PRICE DEFICIENCY

TAIZHOU, CHINA, FEB. 21, 2025 (GLOBE NEWSWIRE) -- CHINA SXT PHARMACEUTICS, INC. (NASDAQ: SXTC) (THE COMPANY OR SXTC), A SPECIALTY PHARMACEUTICAL COMPANY FOCUSING ON THE RESEARCH, DEVELOPMENT, MANUFACTURING, MARKETING, AND SALES OF TRADITIONAL CHINESE MEDICINE PIECES (TCMPS), INCLUDING ADVANCED TCMPS (DIRECTLY-ORAL TCMP AND AFTER-SOAKING-ORAL TCMP), FINE TCMPS, REGULAR TCMPS, AND TCM HOMOLOGOUS SUPPLEMENTS (TCMHS), TODAY ANNOUNCED THAT IT WILL EFFECT A SHARE CONSOLIDATION OF ITS ORDINARY SHARES AT A RATIO OF 1-FOR-8, EFFECTIVE ON FEBRUARY 25, 2025 (THE SHARE CONSOLIDATION). THE COMPANY'S ORDINARY SHARES ARE EXPECTED TO BEGIN TRADING ON A POST-CONSOLIDATION BASIS AT THE OPEN OF THE MARKET SESSION ON FEBRUARY 25, 2025. UPON THE MARKET OPENING ON FEBRUARY 25, 2025, THE COMPANY'S ORDINARY SHARES WILL CONTINUE TO BE TRADED ON THE NASDAQ STOCK MARKET UNDER THE SYMBOL SXTC WITH THE NEW CUSIP NUMBER G2161P157.

CHINA SXT PHARMACEUTICALS, INC. ANNOUNCES SHARE CONSOLIDATION

JIANGSU, CHINA, , OCT. 07, 2024 (GLOBE NEWSWIRE) -- CHINA SXT PHARMACEUTICALS, INC. (SXTC OR THE COMPANY), (NASDAQ: SXTC)ANNOUNCED TODAY THAT ON OCTOBER 3, 2024, THE COMPANY RECEIVED A NOTIFICATION LETTER FROM THE NASDAQ LISTING QUALIFICATIONS STAFF OF THE NASDAQ STOCK MARKET LLC (NASDAQ) NOTIFYING THE COMPANY THAT THE MINIMUM BID PRICE PER SHARE FOR ITS ORDINARY SHARES HAS BEEN BELOW $1.00 FOR A PERIOD OF 30 CONSECUTIVE BUSINESS DAYS AND THE COMPANY THEREFORE NO LONGER MEETS THE MINIMUM BID PRICE REQUIREMENTS SET FORTH IN NASDAQ LISTING RULE 5550(A)(2).

CHINA SXT PHARMACEUTICALS, INC. RECEIVED NASDAQ NOTIFICATION LETTER REGARDING BID PRICE DEFICIENCY

TAIZHOU, CHINA, OCT. 26, 2023 (GLOBE NEWSWIRE) -- CHINA SXT PHARMACEUTICALS, INC. ("SXTC" OR THE "COMPANY"), (NASDAQ: SXTC), A SPECIALTY PHARMACEUTICAL COMPANY FOCUSING ON THE RESEARCH, DEVELOPMENT, MANUFACTURING, MARKETING, AND SALES OF TRADITIONAL CHINESE MEDICINE PIECES ("TCMPS"), INCLUDING ADVANCED TCMPS (DIRECTLY-ORAL TCMP AND AFTER-SOAKING-ORAL TCMP), FINE TCMPS, REGULAR TCMPS, AND TCM HOMOLOGOUS SUPPLEMENTS ("TCMHS"), TODAY ANNOUNCED THAT ON OCTOBER 19, 2023, NASDAQ NOTIFIED US THAT IT HAS DETERMINED THAT FOR THE 10 CONSECUTIVE BUSINESS DAYS, FROM OCTOBER 5, 2023 TO OCTOBER 13, 2023, THE CLOSING BID PRICE OF THE COMPANY'S ORDINARY SHARES HAS BEEN AT $1.00 PER SHARE OR GREATER. ACCORDINGLY, THE COMPANY HAS REGAINED COMPLIANCE WITH LISTING RULE 5550(A)(2) AND NASDAQ HAS CLOSED THIS MATTER.

CHINA SXT PHARMACEUTICALS, INC. REGAINED COMPLIANCE WITH NASDAQ'S MINIMUM BID PRICE RULE

ORDINARY SHARES WILL BEGIN TRADING ON A SPLIT-ADJUSTED BASIS ON OCTOBER 5, 2023 ORDINARY SHARES WILL BEGIN TRADING ON A SPLIT-ADJUSTED BASIS ON OCTOBER 5, 2023

China SXT Pharmaceuticals, Inc.

SXTC

Price

Financials Overview

Financial Reports

No items found.

Press Releases

China SXT Pharmaceuticals, Inc.

SXTC.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

SXTC